LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Farzaneh Atashrazm,1 Nicolas Dzamko2 1Neuroscience Research Australia, Randwick; 2School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia Abstract: Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provid...
Saved in:
| Main Authors: | Atashrazm F, Dzamko N |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2016
|
| Subjects: | |
| Online Access: | https://doaj.org/article/f5632c429f854b89b5083f7a96af03fd |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
by: Xin Liu, et al.
Published: (2021) -
Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
by: Sahar M. El‑Haggar, et al.
Published: (2022) -
Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease
by: Yang Zheng, et al.
Published: (2021) -
The Secrets of Alternative Autophagy
by: Kaja Urbańska, et al.
Published: (2021) -
Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy
by: Yanan Li, et al.
Published: (2021)